Controversias en el uso de la vitamina D como preventivo de la esclerosis múltiple. Revisión de la literatura / Controversies in the use of vitamin D as a preventive of multiple sclerosis. Literature review

La esclerosis múltiple (EM) es una enfermedad desmielinizante que afecta el sistema nervioso central. A pesar de los avances en materia de diagnóstico y tratamiento, se desconocen aún muchos aspectos de su etiopatogenia y fisiopatología. La EM es una de las principales causas de discapacidad neurológica y, por los elevados costos de los tratamientos inmunomoduladores e inmunosupresores, tiene un gran impacto económico en la salud pública. Por ello, se intentaron diversos tratamientos preventivos, como la utilización de la vitamina D. Debido a la acción de la vitamina D sobre el sistema inmune, ha sido prescripta en sujetos de riesgo. Sin embargo, hasta el momento actual, los estudios sobre sus efectos no resultaron concluyentes y persisten las dudas acerca de sus posibles beneficios en materia de prevención. El objetivo de la presente revisión bibliográfica es realizar una puesta al día y destacar los aspectos controversiales en relación al uso de la vitamina D como tratamiento preventivo de la esclerosis múltiple. (AU)

Multiple sclerosis (MS) is a demyelinating disease that affects the central nervous system. Despite advances in diagnosis and treatment, many aspects of its etiopathogenesis and pathophysiology remain unknown. MS is one of the main causes of neurological disability and, due to the high costs of modern immunomodulatory and immunosuppressive treatments, it has a great economic impact on public health. Therefore, numerous efforts have been made in the search for preventive treatments. For this reason, various preventive treatments were tried, such as the use of vitamin D. Due to its action on the immune system, it has been used in subjects at ME risk. However, these studies have been inconclusive to date, and its possible benefits in terms of prevention are still being questioned. The objective of this bibliographic review is to update and highlight the controversial aspects in relation to the use of vitamin D as a preventive treatment of multiple sclerosis. (AU)

Prevalência do diagnóstico de enfermagem Mobilidade Física Prejudicada em pessoas com esclerose múltipla / Prevalence of nursing diagnosis Impaired Physical Mobility in people with multiple sclerosis / Prevalencia del diagnóstico de enfermería Movilidad Física Deteriorada en personas con esclerosis múltiple

Objetivo: identificar a prevalência do diagnóstico de enfermagem Mobilidade Física Prejudicada, suas características definidoras e fatores relacionados em pessoas com Esclerose múltipla e verificar a associação entre ambos e suas razões de prevalência. Métodos: estudo transversal com 113 pacientes em um hospital da região Nordeste do Brasil. Para a análise dos dados utilizou-se os testes de qui-quadrado de Pearson e exato de Fisher, sendo calculadas também as razões de prevalência. Resultados: o diagnóstico esteve presente em 89% da amostra e as características e fatores que apresentaram associação foram: alterações na marcha; instabilidade postural; movimentos descoordenados; redução nas habilidades motoras finas e grossas; depressão; força muscular diminuída e prejuízo músculo esquelético. Conclusão: o diagnóstico apresentou-se com elevada frequência na amostra, o que permite identificar as necessidades de intervenções que diz respeito à capacidade funcional do indivíduo, potencializando seu rendimento funcional e pessoal, através do planejamento do cuidado e da assistência qualificada

Objective: to identify the prevalence of the nursing diagnosis Impaired Physical Mobility, its defining characteristics and related factors in people with multiple sclerosis, and to verify the association between both and their prevalence ratios. Methods: cross-sectional study, with 113 patients in a hospital in the Northeast region of Brazil. Pearson's chi-square test and Fisher's exact test were used to perform data analysis, and the prevalence ratios were calculated. Results: the diagnosis was present in 89% of the sample and the characteristics and factors that presented association were: changes in gait; postural instability; uncoordinated movements; reduction in fine and gross motor skills; depression; decreased muscle strength and skeletal muscle injury. Conclusion: the diagnosis was presented with high frequency in the sample, which allows identifying the needs of interventions that relate to the functional capacity of the individual, enhancing their functional and personal income through the planning of care and qualified care.

Objetivo: identificar la prevalencia del diagnóstico de enfermería Movilidad Física Deteriorada, sus características definitorias y factores relacionados en personas con esclerosis múltiple, y verificar la asociación entre ambos y sus razones de prevalencia. Métodos: estudio transversal, con 113 pacientes en un hospital de la región noreste de Brasil. La prueba de chi-cuadrado de Pearson y la prueba exacta de Fisher se usaron para realizar el análisis de datos, y se calcularon las razones de prevalencia. Resultados: el diagnóstico estuvo presente en el 89% de la muestra y las características y factores que presentaron asociación fueron: cambios en la marcha; inestabilidad postural; movimientos descoordinados; reducción de las habilidades motoras fina y gruesa; depresión; disminución de la fuerza muscular y lesión del esqueleto muscular. Conclusión: el diagnóstico se presentó con alta frecuencia en la muestra, lo que permite identificar las necesidades de las intervenciones que se relacionan con la capacidad funcional del individuo, mejorando sus ingresos funcionales y personales a través de la planificación de la atención y la atención calificada.

There is no benefit in the use of postnatal intravenous immunoglobulin for the prevention of relapses of multiple sclerosis: findings from a systematic review and meta-analysis / Não há benefício do uso de imunoglobulina endovenosa para prevenção de surtos na esclerose múltipla: achados de revisão sistemática e meta-análise

ABSTRACT Multiple sclerosis (MS) is a complex autoimmune and neurodegenerative disease of the central nervous system. Since MS affects mostly fertile women, pregnancy issues often arise in daily practice. The present study assessed the use of postpartum intravenous immunoglobulin (IVIG) in MS. Methods The authors individually searched for records using PubMed, Medline, EMBASE, Cochrane, SciELO, LILACS, and Google Scholar, using the terms "multiple sclerosis" OR "MS" AND "pregnancy" OR "gestation" OR "partum" OR "post-partum" OR "puerperium" AND "immunoglobulin". Results The initial search returned 321 papers. There were 11 eligible articles selected for the review. In total, 380 patients had received post-natal IVIG to reduce the number of postpartum relapses. The unadjusted number needed to treat was 6.3 for the quantitative and 5.8 for the qualitative analyses. Conclusion The therapeutic effect of IVIG for prevention of postnatal relapses in MS could not clearly be established in this meta-analysis.

RESUMO Esclerose múltipla (EM) é uma complexa doença autoimune e neurodegenerativa do sistema nervoso central. Uma vez que EM afeta principalmente mulheres em idade fértil, assuntos relacionados à gravidez frequentemente surgem na prática diária. O presente estudo avaliou o uso pós-parto de imunoglobulina (IVIG) na EM. Métodos Os autores individualmente pesquisaram as bases de dados PubMed, Medline, EMBASE, Cochrane, SciELO, LILACS, e Google Scholar usando os termos "multiple sclerosis" OR "MS" AND "pregnancy" OR "gestation" OR "partum" OR "post-partum" OR "puerperium" AND "immunoglobulin". Resultados A pesquisa inicial retornou 321 artigos. Havia 11 artigos elegíveis para a revisão. No total, havia relato de 380 pacientes que receberam IVIG após a gravidez visando reduzir o número de surtos. O número necessário para tratar não ajustado foi 6,3 para análise quantitativa e 5,8 para análise qualitativa. Conclusão O efeito terapêutico da IVIG para prevenção dos surtos pós-parto na EM não pôde ser claramente estabelecida nesta meta-análise.

Factors associated with adherence to immunomodulator treatment in people with multiple sclerosis

Abstract To determine the association between factors and adherence to immunomodulator treatment in people with multiple sclerosis treated in reference centers. Cross-sectional study conducted with 188 people who used immunomodulators in three reference centers in Ceará from March to July 2012. Adherence was assessed using the Moriskscale and factors were assessed using a questionnaire addressing socioeconomic and personal characteristics, the disease, the use of immunomodulator and educational activities. The determination of the association was expressed in crude and adjusted odds ratio with a 95% confidence interval. Adherence rate was 46% and after the logistic regression model the adherence to immunomodulator treatment was positively associated with the following factors: age 18-38 years, time of diagnosis and treatment between 6 and 24 months, 0-3.5 score in the Expanded Disability Status Scale, perception of treatment benefits, intrinsic and extrinsic motivation, phone contact with the doctor and not missing the return visit. This study is important because it allowed to determine the association between factors and adherence to immunomodulator treatment in multiple sclerosis, contributing to prevention and control actions.

Costo-efectividad del tratamiento con interferón beta en pacientes con síndrome clínico aislado de alto riesgo en Colombia / The cost-effectiveness of interferon beta treatment in patients with a clinically isolated syndrome in Colombia

Introducción. En 85 % de los pacientes con esclerosis múltiple se presenta como manifestación inicial un primer evento desmielinizante o síndrome clínico aislado. En estos casos, el tratamiento con interferón beta retrasa hasta dos años la progresión a esclerosis múltiple. Sin embargo, en Colombia este medicamento es costoso. Objetivo. Determinar si el tratamiento del síndrome clínico aislado con interferón beta es costo-efectivo al retrasar la esclerosis múltiple en dos años. Materiales y métodos. Se realizó un análisis de costo-efectividad empleando un árbol de decisiones basado en la perspectiva del paciente y la sociedad. A partir de una revisión sistemática de la literatura y de conceptos de expertos se definieron las diversas probabilidades. Los costos de la enfermedad se calcularon por medio de la revisión de historias y la aplicación de encuestas a los pacientes atendidos en el Hospital Universitario San Ignacio. Para controlar la incertidumbre se realizó un análisis de sensibilidad mediante una simulación de Monte Carlo con mil pacientes. Resultados. El costo del tratamiento con interferón sobrepasa los Col$ 95´000.000 (US$ 50.000) por paciente durante los dos años. Aproximadamente, 80 % corresponde a los costos del medicamento. El costo de la recaída se acerca a Col$ 39´139.200 (US$ 21.744), y los costos indirectos corresponden a Col$ 10´958.400 (US$ 6.088). La tasa representativa del mercado fue de Col$ 1.800. Con el tratamiento se ganan sólo 0,06 años de vida ajustados por discapacidad (AVAD) adicionales. La razón de costo-efectividad ‘incremental´ (sic.) supera el umbral, incluso en el análisis de sensibilidad. Conclusión. La administración de interferón beta en pacientes con síndrome clínico aislado de alto riesgo en los primeros dos años no es costo-efectiva en Colombia.

Introduction: Approximately 85% of patients with multiple sclerosis have an initial demyelinating event. Treatment with interferon beta delays the progression of multiple sclerosis for nearly two years in patients with a clinically isolated syndrome. In Colombia, interferon is very expensive when compared to other countries. Objective: We sought to determine the cost-effectiveness of a two-year interferon beta treatment within Colombia in patients with a clinically isolated syndrome. Materials and methods: Based on patient and society perspectives, a cost-effectiveness analysis was conducted using a decision tree. A variety of probabilities were defined after a systematic review of the available literature. The disease costs were calculated by reviewing medical charts at the Hospital San Ignacio University and surveys completed by multiple sclerosis patients. To control for uncertainty in these data, analysis of approximately one-thousand patients was performed using Monte Carlo methods. Results: The two-year treatment cost per patient exceeds Col$ 95,000,000 (US$ 50,000). Approximately 80 % of this cost corresponds to medications (US$ 40,500). The price of relapse and indirect costs totals Col$ 41,632,149 (US$ 21,744) and Col$ 11,656,389 (US$ 6,088), respectively. Treatment represents an increase of 0.06 quality-adjusted life years (QALY). The incremental cost-effectiveness ratio exceeds the threshold, regardless of the use of Monte Carlo methods for analysis. Conclusion: Administering interferon beta over the course of two years to high-risk patients with a clinically isolated syndrome is not cost-effective within Colombia.

La esclerosis múltiple en el embarazo: reporte de tres casos en el Hospital Universitario de San Ignacio (HUSI) / Multiple Sclerosis in Pregnancy

Introducción: Se presentan tres casos de pacientes con esclerosis múltiple (EM),diagnosticadas previo al embarazo, y que fueron evaluadas en la Unidad de MedicinaMaterno-Fetal durante sus controles y parto en el Hospital Universitario de SanIgnacio, centro de referencia nivel IV que atiende población embarazada de altoriesgo obstétrico perteneciente al régimen contributivo. Objetivo: Describir lasformas de presentación, fisiopatología, etiología y cuadro clínico de la EM, así comosu comportamiento en el embarazo. Metodología: Se realizó una búsqueda de laliteratura en las bases PubMed, Medline y Cochrane utilizando las palabras clave, pararecopilar información tanto en inglés como en español desde el 2000 al 2011. Despuésse eligieron artículos de revisión y de investigación en EM y embarazo. Conclusiones:Las pacientes con diagnóstico de EM en el embarazo parecen tener un menor riesgode sufrir una recaída, especialmente durante el último trimestre. Sin embargo, vieneseguido de una alta probabilidad de recaída durante los tres meses posteriores, comose observó en dos de los casos descritos en este estudio...

Introduction: Three cases of patients withmultiple sclerosis (MS), diagnosed before pregnancy,and were evaluated at the Departmentof Maternal-Fetal and birth control during theHospital Universitario San Ignacio, level IV referralcenter serving pregnant population highrisk obstetric pertaining to contributory scheme.Objective: To describe the clinical presentationsof the pathophysiology, etiology and clinicalfeatures of MS, as well as their behavior duringpregnancy. Methodology: Electronic search wasconducted in PubMed, Medline, and Cochraneusing the keywords to collect information inboth English and Spanish from 2000 to 2011. Afterreview articles were selected and research inmultiple sclerosis and pregnancy. Conclusions:There seems to be a lower risk of relapse duringpregnancy and especially during the last quarter.However, it is followed by a high probability ofrelapse within three months, as observed in twocases described in this study...

Actualización en el tratamiento de la neuropatía óptica inflamatoria desmielinizante / Updating on the treatment of the demyelinating inflammatory optical neuropathy

Se realizó una revisión bibliográfica con el objetivo de proporcionar una actualización de las drogas que se emplean para retrasar la aparición de esclerosis múltiple en el manejo de la neuropatía óptica inflamatoria desmielinizante. El artículo presenta el origen y la justificación de la terapia esteroidea en este grupo de enfermedad, así como los mecanismos de acción y beneficios de tratamientos más modernos como los inmunomoduladores e inmunosupresores. El trabajo también introduce muchas de las drogas con efectos neuroprotectores que se encuentran en fases experimentales, cuyo uso prevendría la neurodegeneración que se produce a nivel de las células ganglionares retinianas en esta enfermedad neurológica. Las opciones terapéuticas actuales ofrecen variantes de tratamiento adicionales a pacientes con mayores probabilidades de desarrollo de esclerosis múltiple y retrasan la aparición de un segundo brote, así como las secuelas invalidantes que esta suele originar

A bibliographic review was conducted to provide an updating of drugs used to retard the appearance of multiple sclerosis in the management of the demyelinating inflammatory optical neuropathy. Present paper shows the origin and the justification of the steroid therapy in this disease, as well as the mechanisms of action and benefits of more recent treatments, e.g. the ongoing immunomodulations and immunosuppressive ones and also to introduce many drugs in experimental phase having neuroprotection effects whose use will prevent the neurodegenerative effect produced at level of the retinal ganglion cells in this neurologic disease. The current therapeutical options offer variants of additional treatment to those patients with greater possibilities to development multiple sclerosis and retarding the appearance of a second outbreak, as well as its disabling sequelae

Acidos grasos omega-3, enfermedades psiquiátricas y neurodegenerativas: un nuevo enfoque preventivo y terapeútico / Omega-3 fatty acids, neurodegenerative and psychiatric diseases: a new preventive and therapeutic approach

Psychiatric depression and neurodegenerative diseases, such as Alzheimer's disease and multiple sclerosis, have shown a considerable increase in recent decades, particularly in Western countries. These diseases are closely related to the age, socioeconomic status, employment conditions, physical activity, family history or genetic, and in recent years dietary patterns. Omega-3 long-chain polyunsaturated fatty acids (LCPUFA) from marine origin are decisive factors in the prevention and/or treatment of diseases such as cardiovascular diseases, and most recently in psychiatric and neurodegenerative disorders. There is evidence that supplementation with omega-3 LCPUFA may help in preventing the development or in ameliorating the progression of both psychiatric and neurodegenerative diseases. Different clinical trials have demonstrated the efficacy of omega-3 LCPUFA in the prevention and or treatment of neurodegenerative diseases. This review discusses different evidences about the role of omega-3 LCPUFA in the protection against neurodegenerative and psychiatric diseases.

Las enfermedades psiquiátricas y neurodegenerativas han experimentado un considerable incremento en las últimas décadas, particularmente en los países de occidente, destacando entre las de origen psiquiátrico la depresión y entre las neurodegenerativas la esclerosis múltiple y la enfermedad de Alzheimer. Estas enfermedades están estrechamente relacionadas con la edad, nivel socioeconómico, actividad laboral, actividad física, antecedentes familiares o genéticos, y en los últimos años con los patrones dietarios. Los ácidos grasos poliinsaturados de cadena larga (AGPICL) omega-3 de origen marino son considerados actualmente nutrientes determinantes para la prevención y/o el tratamiento de las enfermedades cardiovasculares y más recientemente se ha demostrado el beneficio de la suplementación con AGPICL omega-3 en la prevención y/o el retardo de la progresión de enfermedades psiquiátricas y neurodegenerativas. Diferentes ensayos clínicos han demostrado la eficacia de los AGPICL omega-3 en la prevención y/o tratamiento de enfermedades neurodegenerativas. En esta revisión se discuten diferentes evidencias sobre el rol de los AGPICL omega-3 en la protección de patologías psiquiátricas y neurodegenerativas, destacando el importante rol que tiene la adecuada nutrición en esta prevención.

Beta interferons in clinically isolated syndromes: a meta-analysis

Beta-interferon use in definite multiple sclerosis (MS) has been proven to modify clinical and magnetic resonance imaging outcome. We review and summarize the data of published double-blind, randomized clinical trials to assess, with a meta-analysis the safety and efficacy of beta-interferon on the occurrence of relapses in patients with a first clinical event suggestive of MS. After two years of follow-up, interferon beta decreased the risk of conversion to clinically definite MS 0.51[0.39-0.65], and delayed the time to diagnosis up to 367 days. Side-effects were mild and self limited. Our findings support the efficacy of early treatment with beta-interferon in reducing conversion to clinically defined MS in patients with clinically isolated syndromes.

Já é suficientemente conhecido que a utilização de interferon beta modifica o prognóstico clínico e de ressonância magnética em pacientes com esclerose múltipla (EM). Revisamos e sumarizamos os dados dos ensaios clínicos, duplo-cegos, randomizados e controlados com placebos para analisar, através de meta-análise, a segurança e eficácia dos interferons-beta sobre a ocorrência de recidivas em pacientes com um primeiro evento clínico sugestivo de EM. Após dois anos de seguimento, os interferons-beta diminuíram o risco de conversão para EM clinicamente definida 0,51[0,39-0,65] e retardaram o tempo para diagnóstico em 367 dias. Os efeitos colaterais foram leves e auto limitados. Nossos dados comprovam a eficácia e segurança do interferon-beta em reduzir a conversão para EM clinicamente definida de pacientes com síndromes clínicas isoladas.